Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

Next Previous
X
Search
Trial Profile

A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cridanimod (Primary) ; Medroxyprogesterone; Megestrol
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors AS Kevelt

    • Most Recent Events

    • 13 Jun 2023 This trial has been completed in Czechia (End Date: 17 May 2017), according to European Clinical Trials Database record.
    • 23 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Aug 2016 According to Xenetic Biosciences media release, an Investigational New Drug (IND) application for the Company's product candidate, Virexxa (sodium cridanimod), has been allowed to proceed by the U.S. Food and Drug Administration (FDA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top